USANA Health Sciences, Inc. (USNA) Balance Sheet

Equity has slipped from $533.1M to $526.3M while retained earnings fell from $478.9M to $451.9M, indicating that accumulated losses are now more than offsetting the equity base established during USANA's growth years. The trajectory from net asset accumulation in 2024 through to net contraction in 2026 aligns with the income statement's structural revenue erosion and mounting operating losses, suggesting the balance sheet is no longer insulated from the deteriorating operating picture.

A smaller $6M impairment already occurred between 2025Q3 and 2025Q4, meaning cumulative impairments have erased approximately $35M of the original acquisition premium. With operating losses mounting and revenue declining 5.3% year over year, investors should monitor whether further impairment risk exists against the remaining $109.1M carrying value, as the underlying business does not yet show signs of recovery that would support the residual book value.

With $31.8M of cumulative stock-based compensation over ten quarters diluting ownership while losses shrink the retained earnings base, the quality of USANA's $526.3M equity appears to be deteriorating faster than headline figures suggest. The equity-to-assets ratio has risen to 75%, an unusually high proportion that typically signals either very low asset intensity or, in this case, an equity base propped up by historical accumulation rather than current earnings power.

The current ratio has compressed from 4.03 to 2.66, still healthy in absolute terms but reflecting a materially thinner cushion against the operating losses reported in recent quarters. With the cash trajectory closely tracking the decline in retained earnings and the halt in buybacks since 2025Q2, investors should monitor whether USANA's liquidity buffer can absorb further losses without necessitating either debt issuance or asset sales.